- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01451606
Duloxetine for the Treatment of Chronic Pelvic Pain
September 24, 2019 updated by: Joel Greenspan, University of Maryland, Baltimore
Evaluating Duloxetine's Analgesic Effectiveness in Chronic Pelvic Pain
This study is examining the effectiveness of duloxetine as a treatment for chronic pelvic pain in women.
Duloxetine is FDA approved for the treatment of other pain conditions, including fibromyalgia and diabetic neuropathy.
Study Overview
Status
Terminated
Conditions
Intervention / Treatment
Detailed Description
Chronic pelvic pain in women can be caused by various pathologies, such as endometriosis, fibroids, and adhesions.
Surgical treatment of the pathology often relieves the pain, but a significant number of women continue to have pain, even after visibly successful surgery.
One model explored in this study is that in some cases of chronic pelvic pain, the central nervous system has changed in its processing of pain-related signals, requiring a therapy directed to the Central Nervous System (CNS) to effectively treat the pain.
This model has been supported in studies of other chronic pain conditions, such as fibromyalgia and migraine.
This study will seek to determine whether the analgesic effectiveness of duloxetine is related to the pain state of the individual.
Study Type
Interventional
Enrollment (Actual)
34
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Maryland
-
Baltimore, Maryland, United States, 21201
- University of Maryland, Baltimore
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 50 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Female
Description
Inclusion Criteria:
- premenopausal adult women, aged 18-50
- Have chronic pelvic pain, as defined by the American College of Obstetrics and Gynecology
- Able to read and speak English
Exclusion Criteria:
- Chronic Pelvic Pain (CPP) only presenting in low back or vulva, or only present during menstruation or vaginal intercourse
- Self-report or documentation that all CPP sites were attributed by a prior physician to Irritable Bowel Syndromd (IBS), Interstitial cystitis (IC)/painful bladder syndrome (PBS), urinary tract infection, urinary stones, inflammatory bowel disease (ulcerative colitis or Crohn's disease), cancer or shingles.
- Currently pregnant or lactating
- A primary psychiatric diagnosis of major depression or history of suicide attempt as assessed by medical history. Also, those who would be considered to have Major Depressive Disorder (MDD) on the basis of the Diagnostic and Statistical Manual IV (DSM-IV) criteria will excluded, as well as those selecting "3" or "4" on item #9 of the Beck Depression Inventory (BDI; suicidal ideation).
- A history of bipolar disorder
- A history of seizure disorders
- Orthostatic Hypertension
Exclusions based on the effects of duloxetine:
- Known hypersensitivity to duloxetine or the inactive ingredients in Cymbalta;
- Treatment with an monoamine oxidase inhibitor (MAOI) within 14 days of randomization, or potential need to use an MAOI during the study or within 5 days of discontinuation of the drug;
- Treatment with cytochrome P450 enzyme inhibitors;
- Uncontrolled narrow-angle glaucoma;
- Concurrent use of thioridazine
- Renal Impairment (serum creatinine of 1.5 or greater)
- History of jaundice or hepatomegaly
- Hepatic Insufficiency (elevated aspartate transaminase (AST), alanine transaminase (ALT), bilirubin, or Alkaline Phosphatase), tested at the screening period, after the first week of study medication, and again at the midpoint of the study.
- Participants who are taking Selective serotonin reuptake inhibitors (SSRIs), Selective serotonin and norepinephrine reuptake inhibitors (SSNRIs), monoamine oxidase inhibitors (MAOIs), or tricyclics within 14 days of randomization will be excluded.
- Participants who currently meet DSM-IV diagnostic criteria for Alcohol Abuse or Dependence
- Weight exceeding 285 pounds
- Hyponatremia, as determined by blood test results
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo pill
A pill that looks like the active drug, but does not contain any active ingredients.
|
To serve as placebo for duloxetine.
Administration schedule same as for active drug.
Other Names:
|
Active Comparator: Duloxetine
The drug, Duloxetine, is marketed under the trade name Cymbalta.
It is a serotonergic and noradrenergic reuptake inhibitor (SNRI).
|
30 mg dose once daily, administered orally for 1 week, 60 mg dose once daily, administered orally for 5 weeks, 30 mg dose once daily, administered orally for 1 week
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Rating of Spontaneous Pelvic Pain (0 -10 Scale).
Time Frame: Baseline and 8 weeks
|
The primary clinical efficacy measure is the change in spontaneous (non-evoked) pelvic pain from the baseline period to the end of treatment.
This was assessed by using the 0-10 numerical pain ratings to derive the primary outcome variable of clinical pain intensity difference due to treatment.
Larger values (greater changes in ratings) are better outcomes.
|
Baseline and 8 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Endometriosis Health Profile - 30 Subscale for Functional Limitations Due to Pain
Time Frame: Baseline and 8 weeks
|
This is a questionnaire assessment of functional limitations due to clinical pain.
The range of scores for this subscale is 0-44.
The measure is the change in score from baseline to end of treatment period.
A greater number (change in score) is a better outcome.
|
Baseline and 8 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Investigators
- Principal Investigator: Joel Greenspan, Ph.D., University of Maryland Dental School
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
July 11, 2011
Primary Completion (Actual)
November 4, 2015
Study Completion (Actual)
November 4, 2015
Study Registration Dates
First Submitted
October 11, 2011
First Submitted That Met QC Criteria
October 11, 2011
First Posted (Estimate)
October 13, 2011
Study Record Updates
Last Update Posted (Actual)
September 26, 2019
Last Update Submitted That Met QC Criteria
September 24, 2019
Last Verified
September 1, 2019
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pain
- Neurologic Manifestations
- Pelvic Pain
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Peripheral Nervous System Agents
- Analgesics
- Sensory System Agents
- Psychotropic Drugs
- Neurotransmitter Uptake Inhibitors
- Membrane Transport Modulators
- Antidepressive Agents
- Dopamine Agents
- Serotonin and Noradrenaline Reuptake Inhibitors
- Duloxetine Hydrochloride
Other Study ID Numbers
- HP-00047688
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pelvis Pain Chronic
-
University Hospital of North NorwayUniversity of Tromso; The Royal Norwegian Ministry of Health; Norwegian Fund...Completed
-
Hospital de Clinicas de Porto AlegreCompletedPelvis Pain Chronic | Paraspinous BlockBrazil
-
KK Women's and Children's HospitalDuke-NUS Graduate Medical SchoolWithdrawnEndometriosis of Uterus | Pelvis Pain ChronicSingapore
-
University of Maryland, BaltimoreCompletedPain | Sacroiliac Joint | PelvisUnited States
-
Afyonkarahisar Health Sciences UniversityActive, not recruitingGait | Anatomy | Pelvis | MorphologyTurkey
-
Mayo ClinicNational Cancer Institute (NCI)TerminatedStage III Renal Pelvis Cancer AJCC v8 | Stage III Ureter Cancer AJCC v8 | Stage IV Renal Pelvis Cancer AJCC v8 | Stage IV Ureter Cancer AJCC v8 | Stage III Renal Pelvis and Ureter Cancer AJCC v8 | Stage IV Renal Pelvis and Ureter Cancer AJCC v8 | Stage 0a Renal Pelvis and Ureter Cancer AJCC v8 | Stage... and other conditionsUnited States
-
Sanko UniversityCompletedSpine | Posture | Pelvis | Stomatognathic SystemTurkey
-
University of Alabama at BirminghamBayer Healthcare Pharmaceuticals, Inc./Bayer Schering PharmaCompletedUrothelial Cancer (Urinary Bladder, Ureters, or Renal Pelvis Cancer)United States
-
Clear Guide MedicalJohns Hopkins UniversityUnknownCT Guided Biopsy | CT Guided Drain Placement Within the Abdomen or Pelvis | CT Guided Injection of Muscle or Nerve Within the PelvisUnited States
-
Riphah International UniversityCompletedMyofascial Trigger Point Pain | Quadratus Lumborum Syndrome | Positional Fault of Pelvis | Myofascial Trigger Point in Quadratus LumborumPakistan
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States